A population-based study of progression and risk factors for age-related maculopathy [ 2000 - 2002 ]

Research Grant

Researchers: Catherine Mccarty (Principal investigator) ,  Prof Robyn Guymer

Brief description Age-related macular degeneration (AMD) is a progressive disease, commencing with the less severe age-related maculopathy (ARM), that ultimately can lead to the loss of fine central vision and personal independence. People with advanced AMD generally retain some mobility if their peripheral vision is maintained, but they are unable to perform tasks such as reading, hobbies or recognising people's faces. Unfortunately, the available treatment for AMD, macular laser photocoagulation, benefits only a minority of people with this disease. Until safe and effective treatments for AMD can be developed, identification of major risk factors for the development and progression of AMD is essential to determine if interventions aimed at primary prevention can be initiated. This project will expand on the initial findings of the Visual Impairment Project (VIP), a population-based study of age-related eye disease in a cohort of more than 5000 Victorians aged 40 years and older. Data from the VIP have shown that AMD is the most important ophthalmologic public health problem, particularly since AMD is the major cause of vision impairment in Australia and has the least available treatment options. This study will follow individuals who were identified in the VIP with ARM-AMD to determine the natural history and risk factors associated with the longer term progression of AMD. Particular emphasis will be on determining the role of cardiovascular disease risk factors in AMD progression.

Funding Amount $AUD 776,022.93

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant